Drug Trial Radar · NCT07185997
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Dec 17, 2025
Primary completion
Feb 2029
Study completion Dec 2030
Sponsor
- Lead sponsor
- ArriVent BioPharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC mutations, and who have not received any prior therapy for advanced disease. Participants will be randomized in a 1:1 ratio to treatment with firmonertinib or osimertinib or afatinib and will take the assigned dose daily.
Conditions
- Non-Small-Cell Lung Cancer
- Metastatic Non-Small-Cell Lung Cancer
- Advanced Non-Small-Cell Lung Cancer
- EGFR P-Loop and Alpha C-Helix Compressing
- EGFR PACC
- EGFR Uncommon Mutations
Interventions
FirmonertinibDrug
240 mg oral, daily firmonertinib tablet
EGFR-TKI inhibitor based on investigator's choiceDrug
osimertinib 80 mg oral, daily tablet OR afatinib 40 mg oral, daily tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) determined by blinded independent central review (BICR)Time frame: Until progression or death, assessed up to approximately 4 years
- Confirmed overall response rate (ORR) as determined by BICRTime frame: Until progression or death, assessed up to approximately 3 years
Locations
141 sites in 17 countries. Site status is shown where the registry gives one.
St. Jude Medical Center
Fullerton, California · Recruiting
USC/Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Providence St. Joseph Hospital
Orange, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
UCSF Medical Center-Mission Bay
San Francisco, California · Recruiting
Kaiser Permanente Medical Center
Vallejo, California · Recruiting
University of Colorado Health
Aurora, Colorado · Recruiting
Illinois Cancer Specialists
Arlington Heights, Illinois · Recruiting
University of Illinois Hospital and Health Sciences Systems
Chicago, Illinois · Recruiting
Henry Ford Cancer Institute
Detroit, Michigan · Recruiting
Northwell Health/R.J. Zuckerberg Cancer Center
Lake Success, New York · Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Recruiting
Columbia University Medical Center
New York, New York · Recruiting
Ohio State University Hospitals
Columbus, Ohio · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
Texas Oncology
Dallas, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Shenandoah Oncology, P.C.
Winchester, Virginia · Recruiting
Swedish Cancer Institute
Edmonds, Washington · Recruiting
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia · Recruiting
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
GenesisCare North Shore Health Hub
St Leonards, New South Wales, Australia · Recruiting
Austin Health
Heidelberg, Victoria, Australia · Recruiting
Alberta Health Services, Tom Baker Cancer Centre
Calgary, Alberta, Canada · Recruiting
University of Alberta - Cross Cancer Institute (CCI)
Edmonton, Alberta, Canada · Recruiting
BC Cancer Vancouver Centre
Vancouver, British Columbia, Canada · Recruiting
Brampton Civic Hospital, William Osler Health Centre
Brampton, Ontario, Canada · Recruiting
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada · Recruiting
Sunnybrook Research Institute
Toronto, Ontario, Canada · Recruiting
Princess Margaret Cancer Centre - University Health Network
Toronto, Ontario, Canada · Recruiting
Anhui Provincial Hospital
Hefei, Anhui, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University Cancer Hospital (PKUCH)/Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Zhongshan Hospital Xiamen University
Xiamen, Fujian, China · Recruiting
Showing 40 of 141 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.